Atopic Dermatitis in 2025: Year in Review

In 2025, the HCPLive team spotlighted an array of unique developments in dermatology news centered on atopic dermatitis treatment, including summarizing key approvals from the US Food and Drug Administration (FDA) and the release of significant clinical trial data shaping the evolving therapeutic landscape of eczema management.

Beyond regulatory decisions and clinical research advances, 2025 also featured a series of HCPLive podcast episodes or feature articles aimed at atopic dermatitis. In the site's Year in Review overview, HCPLive has curated some of the most significant updates and thought leadership shared on the HCPLive platform, providing readers with a comprehensive look back at atopic dermatitis–related news and a peak at trends projected to impact the field moving forward:

FDA News

FDA Approves Ruxolitinib Cream for Pediatric Patients with Atopic Dermatitis

In September 2025, ruxolitinib cream (OPZELURA) was approved by the FDA for children aged 2 - 11 years with moderate-to-severe atopic dermatitis. This announcement by the Incyte Corporation highlighted ruxolitinib cream’s indication for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised children ≥ 2 years of age whose atopic dermatitis is not well controlled with topicals or when such drugs are not recommended. The FDA’s decision follows positive phase 3 TRuE-AD3 trial findings.

Delgocitinib (Anzupgo) Scores FDA Approval for Chronic Hand Eczema

Delgocitinib (Anzupgo) cream was also approved in 2025 for the treatment of moderate-to-severe chronic hand eczema (CHE). LEO Pharma highlighted delgocitinib cream’s indication for CHE in adults who have had an inadequate response to, or for whom topical corticosteroids are not advisable, and its approval was based on data from the DELTA 1 and DELTA 2 clinical trials.

FDA Approves Roflumilast (Zoryve) Cream 0.05% for Atopic Dermatitis in Children Aged 2-5 Years

In October 2025, Arcutis Biotherapeutics’s roflumilast (Zoryve) cream 0.05% was approved by FDA officials for the topical treatment of mild to moderate atopic dermatitis in children 2-5 years of age. The decision to approve this medication was based on findings from the INTEGUMENT-PED phase 3 study, the INTEGUMENT-OLE long-term extension study, and a phase 1 pharmacokinetic analysis. The decision represents the sixth FDA approval for the roflumilast armamentarium in just over 3 years.

FDA Grants Fast Track Designation to Rezpegaldesleukin for Atopic Dermatitis

In February 2025, Nektar Therapeutics announced the FDA’s decision to grant Fast Track designation to rezpegaldesleukin for the treatment of adult and pediatric patients living with moderate-to-severe atopic dermatitis. The medication is an investigational biologic formulated to stimulate the proliferation of regulatory T cells by targeting the interleukin (IL)-2 receptor complex. The phase 2b REZOLVE-AD study assessed rezpegaldesleukin's efficacy, enrolling 398 patients and assessing patients’ mean EASI score improvements.

Trial Updates and New Guidelines

Notable Findings on Lebrikizumab in ADmirable Study Assessing Patients with Skin of Color

During the Revolutionizing Atopic Dermatitis (RAD) Conference, new data on the efficacy of lebrikizumab (Ebglyss) for atopic dermatitis in adult and adolescent patients with skin of color were presented. These findings pointed to improvements observed by the phase 3b ADmirable study investigators over 24 weeks. The HCPLive team spoke at RAD with Andrew Alexis, MD, MPH, an ADmirable investigator and professor of clinical dermatology at Weill Cornell Medicine, on these new lebrikizumab data and their implications for patients with skin of color.

Phase 3 Data Show Amlitelimab Effective in Adults, Adolescents with Atopic Dermatitis

In phase 3 findings released in September 2025, amlitelimab therapy, administered every 4 or every 12 weeks, was shown to significantly improve patients’ level of skin clearance and to significantly reduce severity versus placebo among those with atopic dermatitis at 24 weeks. The findings, announced by Sanofi SA, were the result of the global COAST 1 trial (NCT06130566) assessing the use of amlitelimab, a fully human, non–T-cell depleting monoclonal antibody directed against OX40-ligand (OX40L), in those aged 12 years and older with moderate-to-severe atopic dermatitis.

Topline Results Announced on Rocatinlimab for Adults with Atopic Dermatitis

In preliminary results from the ASCEND study, rocatinlimab therapy was shown by investigators to provide sustained skin clearance and itch improvements for individuals with moderate to severe atopic dermatitis. The drug also maintained a favorable long-term safety profile and low rates of discontinuation. The ASCEND analysis enrolled nearly 2600 participants, assessing the long-term efficacy and safety of rocatinlimab over 104 weeks with dosing every 4 or 8 weeks.

Next Step for OX40/OX40L: Real-World Data in Atopic Dermatitis, With Raj Chovatiya, MD, PhD

Raj Chovatiya, MD, PhD, of Northwestern Feinberg School of Medicine, spoke in an interview with HCPLive on the promise of the OX40/ OX40L target as a first-line treatment for conditions such as atopic dermatitis, asthma, and chronic urticaria in recent phase 2 and 3 clinical research. Chovatiya noted the impact of the OX40-targeted therapies and highlighted his own anticipation toward seeing some more sub-analyses and better understanding what it means to be truly naive, or treatment-experienced, and to be treated with medications such as rocatinlimab and amlitelimab.

Feature Content/Podcasts

Rethinking the Black Box: JAK Inhibitors Find Their Place in Dermatology

In an editorial feature posted in October 2025, the HCPLive team interviewed a series of experts in dermatology to highlight perceptions in Janus kinase (JAK) inhibitor safety, to explore the initial excitement surrounding such medications, the subsequent caution resulting from black box warnings, and the more recent confidence expressed in recent months. JAK inhibitors have seen an explosion in approvals and are fast becoming key players in the management of conditions such as psoriasis, alopecia areata, and atopic dermatitis.

The Skin–Brain Axis: Emerging Evidence Transforming Dermatologic Care

In an October 2025 feature, 3 experts were interviewed regarding the mounting evidence suggesting the brain and skin are more closely connected than previously understood. This feature highlighted data linking inflammatory skin diseases such as atopic dermatitis to neurocognitive and emotional health outcomes. This feature touched on the skin–brain axis, a bidirectional pathway of neural, immune, and endocrine signals, as a key driver of both dermatologic and psychiatric comorbidities.

HCPLive Five - Dermatology Updates at RAD Conference 2025

In this edition of ‘HCPLive Five,’ HCPLive highlighted the 2025 RAD Conference, touching on both new data and sessions by dermatology leaders presenting at RAD. Insights on the management, pathophysiology, and therapeutic innovations for atopic dermatitis were all highlighted in HCPLive’s on-site coverage, and this summary included 5 standout video interviews from the meeting. These interviews included conversations related to allergy's connection to atopic dermatitis, concerns over JAKis, dose flexibility, and more.